

























































Site-Specific Antibody Fragment Conjugates for Reversible
Staining in Fluorescence Microscopy
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Antibody conjugates have taken a great leap forward as tools in
basic and applied molecular life sciences that was enabled by
the development of chemoselective reactions for the site-
specific modification of proteins. Antibody-oligonucleotide
conjugates combine the antibody’s target specificity with the
reversible, sequence-encoded binding properties of oligonu-
cleotides like DNAs or peptide nucleic acids (PNAs), allowing
sequential imaging of large numbers of targets in a single
specimen. In this report, we use the Tub-tag® technology in
combination with Cu-catalyzed azide-alkyne cycloaddition for
the site-specific conjugation of single DNA and PNA strands to
an eGFP-binding nanobody. We show binding of the conjugate
to recombinant eGFP and subsequent sequence-specific anneal-
ing of fluorescently labelled imager strands. Furthermore, we
reversibly stain eGFP-tagged proteins in human cells, thus
demonstrating the suitability of our conjugation strategy to
generate antibody-oligonucleotides for reversible immunofluor-
escence imaging.
Introduction
Proteins, especially antibodies, have been widely used as
important tools in basic research and more recently as
diagnostic and therapeutic agents.[1,2] Site- or residue-specific
modification of antibodies with additional moieties ranging
from small chemical compounds to large polypeptides has
further expanded their field of use. This advancement was
enabled by the development of chemoselective or bioorthogo-
nal reactions and incorporation of unnatural amino acids into
antibodies.[3] Antibody-oligonucleotide conjugates represent
particularly interesting modalities, as they combine two key
advantages of their building blocks in a single entity: specific
antigen binding of antibodies with sequence-dependent hy-
bridization of oligonucleotides to complementary strands. The
former allows specific binding of target proteins in complex
contexts such as cells, while the latter can be used for tunable,
thus, reversible attachment of additional functionalities such as
fluorophores. Unsurprisingly, protein-oligonucleotide conju-
gates have seen great use in a variety of applications ranging
from protein immobilization,[4] bioanalytics[5–7] to material
science.[8–10] Moreover, antibody-oligonucleotide conjugates
have been employed in fluorescence and super resolution
microscopy[11,12] as they resolve the limitations that come with
standard fluorophore-conjugated antibodies.
Although fluorophore-conjugated antibodies are one of the
most common staining reagents due to their broad spectrum of
targets, the virtually irreversible binding of antibodies and the
spectral overlap between fluorophores heavily limit the number
of individual targets that can be investigated at the same time.
To overcome this problem, efforts have been devoted to
develop protocols to either elute the antibodies[13,14] or chemi-
cally inactivate the fluorophores in between successive imaging
rounds. However, these techniques involve harsh washing steps
and thereby potentially alter epitope accessibility for the
following imaging probes. Thus, elution of the previous probe
should ideally be rapid and buffer conditions mild to preserve
sample integrity. An elegant way to achieve this goal was
developed for super-resolution microscopy called DNA-point
accumulation for imaging in nanoscale topography (DNA-
PAINT).[15] DNA-PAINT exploits the transient binding of fluoro-
phore-coupled oligonucleotides (imager strands) to their com-
plementary sequence (docking strands) for reversible immobili-
zation. The tunability of the binding strength between
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oligonucleotides allows for rapid exchange of fluorophores
under mild washing conditions.[16,17]
Techniques to generate oligonucleotide-conjugated anti-
bodies have subsequently received increasing interest. Com-
mon protocols involve bifunctional linkers that target exposed
residues of amino acids on the protein surface.[18–20] However,
conjugation stoichiometry is challenging to control depending
on the abundance of the reactive surface residue. Other
approaches that allow site-specific conjugation rely on guiding
the reaction with a complementary template,[21] the incorpo-
ration of unnatural amino acids,[22,23] targeting unique or rare
amino acids on native proteins[24] or the use of tag-enzyme
pairs.[25–28] We previously established the Tub-tag® conjugation
technology for bioorthogonal, chemoenzymatic labelling of
proteins[29,30] The Tub-tag® technology makes use of the enzyme
tubulin tyrosine ligase (TTL) as a highly flexible tool for protein
modification, that accepts a broad range of tyrosine derivatives
as substrates enabling various bioorthogonal chemistries. We
demonstrated its suitability for functionalization with small
molecules[31] as well as protein-protein ligation.[32] In this work,
we present the Tub-tag® mediated, efficient and site-specific
generation of nanobody-DNA and -PNA conjugates in a 1 : 1
stoichiometry that can readily be used for reversible staining in
confocal fluorescence microscopy.
Results and Discussion
Our approach combines enzyme-catalyzed ligation of a reactive
chemical handle to an eGFP-binding nanobody (GBP) with CuI-
catalyzed alkyne-azide cycloaddition (CuAAC) to conjugate the
oligonucleotide (Figure 1A). As proof-of-principle, we employed
these conjugates for reversible staining of eGFP-fusion protein
expressing cells in confocal fluorescence microscopy (Fig-
ure 1B). In a first step, TTL recognizes the C-terminal Tub-tag®
on the protein and site-specifically ligates O-propargyl-l-
tyrosine to the C terminus of the antibody. This introduces an
alkyne group to the protein that can be used as a chemical
handle for following reactions. Second, we used CuAAC for
conjugation of an azide-containing DNA or PNA to form a stable
bond between antibody and oligonucleotide at a 1 : 1 stoichi-
ometry. We envisioned that the unique characteristics of PNAs
such as higher melting temperature and uncharged backbone
would additionally broaden the general applicability of this
strategy alternative to DNA conjugation.
We first set out to generate antibody-DNA/-PNA conjugates
by using Tub-tag® technology and CuAAC based on previously
published optimizations[32] and used eGFP-binding protein as a
model antibody fragment. SDS-PAGE and Coomassie staining
confirmed efficient conjugation of both azide-DNA (yield:
55.9 %) and azide-PNA (yield: 66.1 %) to alkyne-modified GBP at
4x molar excess of azide-oligo over nanobody (Figure 2A).
We hypothesized that especially the DNA oligonucleotide
would strongly influence the total charge of the conjugated
molecule so that unfunctionalized alkynyl GBP can be separated
from the conjugate. Therefore, we performed mass spectrome-
try (Figure S1) and anion-exchange chromatography (AEX) to
further validate our observation from the gel electrophoresis.
Notably, we observed a strong shift towards higher ionic
strength for GBP-DNA conjugate compared to unfunctionalized
alkynyl GBP indicating stronger interaction with the stationary
phase (Figure 2B). In addition, the GBP-DNA conjugate and free
azide-DNA were not separable to baseline, thus suggesting that
binding to the stationary phase is mediated by the DNA
oligonucleotide to a major degree. Nevertheless, AEX allows for
removal of unconjugated alkynyl antibody as demonstrated by
SDS-PAGE (Figure 2A) and partial depletion of free DNA in the
final product. In contrast, the antibody-PNA conjugates shifted
towards lower ionic strengths. In accordance with this observa-
tion, free azide-PNA molecules eluted during the column wash
because PNA does not have a strong negative charge (Fig-
ure 2B).
Taken together, these findings not only confirm that our
chemoenzymatic functionalization approach is capable of
generating protein-oligonucleotide conjugates with high effi-
ciency, but also that unfunctionalized alkynyl protein is
separable from the conjugate product by AEX and free azide-
oligonucleotides can be at least partially depleted.
Figure 1. Functionalization strategy for generating nanobody-oligonucleo-
tide conjugates and usage for reversible staining in fluorescence microscopy.
A) Schematic representation of the site-specific ligation of single-stranded
oligonucleotides to the C terminus of Tub-tagged nanobodies in a two-step
process. First, an alkyne handle is introduced by the tubulin-tyrosine ligase
(TTL)-catalyzed ligation of O-propargyl-l-tyrosine to the Tub-tag. Second,
azide-DNA or azide-PNA is conjugated to the alkyne handle by CuAAC. B)
Reversible immunofluorescence staining by hybridization of a fluorescent
imager strand with the nanobody-oligonucleotide conjugate. Stripping of
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To determine whether the antibody-oligonucleotide can
bind both target and the complementary imager strand, we
performed an in vitro binding assay on immobilized purified
protein using either eGFP (target) or BSA (negative control). We
detected strong signals for both DNA and PNA conjugate when
the sample was hybridized with the complementary imager
DNA-strand. Using either BSA as target protein or a non-
complementary imager strand lead only to a minor increase of
fluorescence (Figure 3 top). This result confirmed that the
functionality of both the antibody and the DNA docking strand
was preserved by our conjugation strategy, as our conjugate
was able to bind both eGFP and the complementary imager
strand. Based on these findings, we were prompted to test our
conjugate on fixed cells, which provide a much more complex
environment that could potentially lead to a higher degree of
unspecific staining. Therefore, we used transiently transfected
HEK293F cells expressing eGFP-actin fusion protein, and
repeated the staining similar to the previous experiment
(Figure 3, bottom). We observed the strongest signal in eGFP-
actin-transfected cells when staining with the complementary
imager strand. Untransfected cells that do not express eGFP did
not show elevated levels of fluorescence in the imager strand
channel. Staining with noncomplementary imager strand
resulted in a minor increase of background fluorescence in both
transfected and untransfected cells, suggesting that this effect
is inherent to unspecific binding of the DNA or fluorophore
itself to cellular components but not due to interaction with the
docking strand. Antibody-PNA conjugate yielded higher
fluorescence intensity, potentially indicating stronger binding
of the DNA imager strand to PNA than to DNA as reported
previously.[33]
These promising results encouraged us to test whether the
conjugate can be used for reversible immunostaining in
confocal fluorescence microscopy. To this end, we stained fixed
HEK293F and HeLa cells expressing either eGFP-LaminB1 or
eGFP-PCNA fusion proteins, respectively, with DNA-conjugated
nanobody. To verify that the imager strand can be detached
from the docking strand, we stripped the samples with
formamide containing buffer and performed restaining using
an imager strand with the same sequence but different
fluorophore as visualized in Figure 1B. For both target proteins,
we observed distinct nuclear staining with strong colocalization
of imager strand and eGFP-LaminB1 or eGFP-PCNA, respectively
(Figure 4). After stripping off the first imager strand, we
detected practically no remaining fluorescence although we
used a highly sensitive detector, thus suggesting that the
imager strand was efficiently detached from the DNA-docking
strand. Restaining with a second imager strand led again to
Figure 2. TTL-catalyzed enzymatic incorporation of O-propargyl-l-tyrosine and subsequent conjugation of azide-modified 15 bp DNA and PNA strands by
CuAAC. A) Coomassie staining of SDS gels of functionalized alkynyl GBP (cropped sections, contrast adjusted, full images can be found in Figure S2). Alkynyl
GBP was generated by TTL-catalyzed ligation of O-propargyl-l-tyrosine (298 μM GBP-TT, 29.8 μM TTL and 10 mM O-propargyl-l-tyrosine for 3 h at 30 °C).
Conjugation with azide-DNA was performed by using 40 μM akynyl GBP and 160 μM azide-DNA; conjugation with azide-PNA was performed by using 60 μM
alkynyl GBP and 120 μM azide-PNA (0.25 mM CuSO4, 1.25 mM THPTA, 5 mM aminoguanidine and 5 mM sodium ascorbate). B) Analytical anion-exchange
chromatography of the raw conjugation products of (A). Absorption (280 nm) is normalized to the strongest signal. The peak marked with an asterisk
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colocalization of eGFP and imager strand fluorescence (Fig-
ure 4). Thus, this result demonstrates that the nanobody-DNA
conjugate remains intact during the washing and that the
staining is reversible. In contrast, nanobody-PNA conjugates
showed residual fluorescence after washing in cell staining
(Figure S4) as well as in vitro binding assays (Figure S5). This
observation is potentially due to stronger hybridization of PNA/
DNA duplexes and might be resolved by optimization of
washing conditions or altering the sequence to lower hybrid-
ization temperatures. For nanobody-DNA and -PNA conjugates,
we observed minor background staining of the nucleus in all
cells even without expression of eGFP (Figure S6); this supports
the assumption that the background is likely caused by
nonspecific interaction of the DNA-imager strand with genomic
DNA.
In summary, we have shown herein a novel conjugation
technique for generation of nanobody-DNA and -PNA con-
jugates. Our approach allows the site-specific conjugation in
1 : 1 stoichiometry with high efficiency as shown by SDS-PAGE
and anion-exchange chromatography. In addition, binding
assays on immobilized protein show a strong and specific
staining towards the epitope of the antibody. Moreover, we
demonstrate quick and efficient reversibility of the staining by
using confocal fluorescence microscopy, which is a key require-
ment for multiplexing via fluorophore exchange. Thus, our
technology provides a new tool for chemo-enzymatic gener-
ation of protein-oligonucleotide conjugates. The defined 1 : 1
stoichiometry of our conjugation strategy provides a valuable
advantage over currently state-of-the-art functionalization of
surface exposed amino acids, where neither the stoichiometry
nor the functionalization site is defined.
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Figure 3. Nanobody-oligonucleotide conjugates exhibit bind to their target
protein and allow sequence-specific annealing of fluorescently labelled
imager strands. Top: Binding of nanobody-oligonucleotide conjugates to
purified eGFP and annealing of a either complementary fluorescent imager
strand (comp probe A594) or noncomplementary fluorescent imager strand
(non-comp probe A647). Bottom: Binding of nanobody-oligonucleotide
conjugates to eGFP-actin expressing cells. Imager strands were used as in
the top panels. Fluorescence signal intensity per well is represented by the
respective color coding.
Figure 4. Nanobody-oligonucleotide conjugates are suitable for reversible
staining of cells in fluorescence microscopy. Top: Staining of HEK293F cells
expressing eGFP-LaminB1. eGFP-LaminB1 is stained by binding of the
nanobody-DNA conjugate and subsequent annealing of a complementary
imager strand leading to colocalized signal of imager strand and eGFP.
Disruption of the interaction of imager and docking strand leads to almost
complete removal of fluorescence, allowing for restaining with a comple-
mentary imager strand in a different channel. Bottom: Staining of HeLa
Kyoto cells expressing eGFP-PCNA. Staining was performed identically to the
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We present a novel strategy for the
efficient and site-specific generation
of nanobody-oligonucleotide conju-
gates in a 1 : 1 stoichiometry by Tub-
tag-mediated conjugation. We show
a proof-of-concept that these conju-
gates can readily be used for reversi-
ble staining in confocal fluorescence
microscopy.
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